Background: Biomarkers that would help prognosticate outcomes and guide treatment of
patients with severe coronavirus disease 2019 (COVID-19) are currently required. We aimed …

Objective To delineate the characteristics and clinical significance of plasma inflammatory
cytokines altered in COVID-19. Design Retrospective, single-centre cohort study. Setting …

The severity of COVID-19 is largely determined by the inflammatory response, a “Cytokine
storm,” that involves both pro-and anti-inflammatory cytokines. In the current study we …

Since the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, it has rapidly
spread across many other countries. While the majority of patients were considered mild …

Introduction Coronavirus disease 2019 (COVID-19) appeared in China in December 2019
and has spread around the world. High Interleukin-6 (IL-6) levels in COVID-19 patients …

Background Interleukin-6 (IL-6), a proinflammatory cytokine, has been reported to be
associated with disease severity and mortality in patients with coronavirus disease 2019 …

Background High cytokine levels have been associated with severe COVID-19 disease.
Although many cytokine studies have been performed, not many of them include …

BACKGROUND Elevated levels of inflammatory cytokines have been associated with poor
outcomes among COVID-19 patients. It is unknown, however, how these levels compare …

The prognostic value of interleukin-6 in COVID-19 needs to be clarified. In this retrospective
study, COVID-19 patients treated in Renmin Hospital of Wuhan University from Jan 7 to Feb …

Objectives We aimed to explore cytokine profile in patients as it relates to Coronavirus
Disease 2019 (COVID-19) severity, and to establish a predictive cytokine score to …